Abstract:Abstract Background Amiodarone may cause pulmonary fibrosis. However, very few studies have investigated this possible association. This study will evaluate whether amiodarone is associated with pulmonary fibrosis, and furthermore, if there is an exposure-response relationship. Method and results Using Danish national patient registries, we conducted an observational population-based study. Individuals diagnosed with pulmonary fibrosis were identified between 1996 and 2020 using ICD codes and then included in a nested case-control study, where cases were matched with 5 controls. The exposure to amiodarone was defined by dispensed amiodarone recipes from the national prescription registry. Cox regression analysis was used to derive the crude hazard ratio (HR) and the confidence interval (CI). The analyses were also adjusted and stratified for pre-specified comorbidities to derive multivariate Hazard ratio. Furthermore, we analysed the outcome in respect to amiodarone exposure time (<3 months, 3-6 months, 6-12 months, 1-3 years, 3-5 years, over 5 years) and also in respect to the cumulative dosage. A total of 27 948 cases diagnosed with pulmonary fibrosis over the 24 years period of study in Danish population were matched with 139 740 controls. The average age was 69 years and 45% was females. We found that amiodarone treatment was associated with significant risk of pulmonary fibrosis (HR: 4.20, 95%CI: [3.83-4.60], p<0.001). After adjusting for comorbidities including hypertension, diabetes mellitus, asthma, chronic obstructive pulmonary disease, ischemic heart disease, heart failure, stroke, any cancer, liver failure, chronic kidney disease, and alcohol, the association remained significant (HR:2.55, 95%CI: [2.30-2.82], p<0.001) (Figure 1), and its remained also significant after excluding COPD patients from the population (HR: 3.93, 95%CI: [3.50-4.40], p<0.001). Finally, the treatment exposure relationship, 0-3 months (HR:2.34, 95%CI [1.82-3.02], p<0.001), and over 5 years (HR: 5.90, 95%CI [4.56-7.65], p<0.001) (figure 2), and dose response relationship, 0-18gm (HR: 2.48, 95%CI: [1.93-3.18], p<0.001), 120-240gm (HR: 4.34, 95%CI: [3.46-5.45], p<0.001), and over 840gm (HR: 7.06, 95%CI: [3.08-16.15], p<0.001) (figure 3). Conclusion Amiodarone use was found associated with an independent incident pulmonary fibrosis, 4-fold crude risk and with a more than 2-fold hazard already within the first 3 months of treatment. The association showed also a dose- and duration relationship, where larger doses and longer treatment were associated with higher hazard of pulmonary fibrosis.

Pulmonary adverse events associated with amiodarone: a real-world pharmacovigilance study based on the FDA adverse event reporting system

Progress in study of amiodarone induced pulmonary toxicity

Case Report: Amiodarone-induced multi-organ toxicity

Analysis of a Serious Adverse Reaction of Pulmonary Fibrosis Caused by Dronedarone

Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study

Amiodarone and the risk for pulmonary fibrosis. A Danish nationwide study

Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database

Risk of respiratory, thoracic, and mediastinal disorders associated with endothelin receptor antagonists and prostacyclin-related drugs in pulmonary hypertension: a disproportionality analysis based on FAERS

Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Current Status of Antiarrhythmic Drug Use and Safety Assessment in Chinese Patients with Atrial Fibrillation

Cardiac adverse events associated with statins in myocardial infarction patients: a pharmacovigilance analysis of the FDA Adverse Event Reporting System

Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS

Amiodarone-Induced Multi-Systemic Toxicity Involving the Liver, Lungs, Thyroid, and Eyes: A Case Report

Impact on QTc Interval and Safety Evaluation of Amiodarone for Non-Valvular Atrial Fibrillation Patients

Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases

ORENITRAM's decadal journey: unveiling safety profiles and adverse event through a real-world pharmacovigilance study of FAERS events

Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?

Analysis of risk factors for QT interval prolongation induced by intravenous amiodarone administration

Cardiovascular toxicity profile of doxorubicin: data mining of the FDA adverse event reporting system (FAERS)